malsen
CUSTOMER STORIES
Our clients range from large multinationals, through to small one person startups. All of which need to find efficient ways to comply to the latest regulations for medical and pharmaceutical products.
Something else
EpiGuard. EpiShuttle is a medical isolation and transportation system designed for optimal safety and numerous treatment options during patient loading and transport. The unit is a single-patient isolator made of solvent-resistant materials. EpiShuttle can be carried and is compatible with leading ambulance-stretcher undercarriage EMS systems.
Malsen Medical have been Involved with EpiGuard for several years to set up their production, regulatory strategy, QMS and technical documentation.
Something more
The HAT is based on an idea by the Norwegian Air Ambulance Foundation (SNLA). Their paramedics and rescuers were lacking a device that would immediately start and activate heat treatment, whilst leaving them room for treating the patient. The development is currently coordinated with SNLA and Minitech AS, a Norwegian leader in medical device heating systems.
We are very proud to have supported the Norwegian Air Ambulance and Minitech AS with the engineering and regulatory submittal for this project through all stages of development and MDR submission in just 2 years.
Yet more
The falsification directive (FMD) was issued in 2011 and came into force on 9 Feb 2019 to ensure that all prescription medicines sold in Europe are verified to be authentic prior to being sold. The system is a pan-European IT system that affects all involved in the pharmaceutical industry.
Malsen Medical has been working on this project from around 2015 in various roles. We worked both in testing the system globally prior to launch and building up the QMS systems locally in several countries and fostering pan-European collaboration. We continue to support and develop the system further in Europe and now also in Africa.
Vision
Be the partner of choice for companies operating in medical device, vitro diagnostics and the pharmaceuticalsectors.
